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with both PedsQL and CHIP-CE for all parent/carer 
(P < 0.01) and most child (P < 0.05) ratings; more ADHD 
symptoms were associated with poorer HRQoL. These 
data demonstrate that ADHD has a significant impact on 
HRQoL (as observed in both parent/carer and child rat-
ings), which seems to be greater than that for children with 
T1DM.
Keywords Attention deficit-hyperactivity disorder · 
Diabetes mellitus · Quality of life · Children
Introduction
Health-related quality of life (HRQoL) is a complex, mul-
tifaceted construct that describes an individual’s percep-
tion of the impact of their health status on their physi-
cal, psychological and social functioning. HRQoL can be 
measured using a wide range of instruments [1–3]. Most 
of the currently available HRQoL measures are generic 
(non-disease specific). Generic measures used in clinical 
research include, for example, the Child Health Question-
naire Parent Form 50, Child Health and Illness Profile-child 
edition (CHIP-CE), Paediatric Quality of Life Inventory 
(PedsQL) and EuroQoL Five-Dimension Questionnaire [3, 
4]. Generic HRQoL instruments assess broad constructs of 
HRQoL and can be used across different patients irrespec-
tive of their illness(es), but may not be sensitive to some 
disease-specific issues [3]. Disorder-specific instruments 
for attention-deficit/hyperactivity disorder (ADHD) include 
the ADHD Impact Module for children and adults, and the 
adult ADHD quality-of-life scale [5–7].
Clinicians, academics and regulators are becom-
ing increasingly interested in the potential for HRQoL 
measures to be used as an index of clinical change and 
Abstract The impact of attention-deficit/hyperactiv-
ity disorder (ADHD) on health-related quality of life 
(HRQoL) is reported to be similar to that of other mental 
health and physical disorders. In this cross-sectional study, 
we hypothesized that children with ADHD and children 
with type 1 diabetes mellitus (T1DM) would have sig-
nificantly worse HRQoL compared with healthy children, 
and that better clinical status in ADHD and T1DM would 
be associated with better HRQoL. Children were recruited 
from three outpatient services in Scotland. Responses to 
two frequently used validated HRQoL instruments, the 
Paediatric Quality of Life Inventory (PedsQL) and Child 
Health and Illness Profile-child edition (CHIP-CE), were 
obtained from parents/carers and children (6–16 years) 
with/without ADHD or T1DM. Child and parent/carer-
completed HRQoL measurements were evaluated for 213 
children with ADHD, 58 children with T1DM and 117 
healthy children (control group). Significantly lower self 
and parent/carer ratings were observed across most PedsQL 
(P < 0.001) and CHIP-CE (P < 0.05) domains (indicating 
reduced HRQoL) for the ADHD group compared with the 
T1DM and control groups. Parent/carer and child ratings 
were significantly correlated for both measures of HRQoL 
(PedsQL total score: P < 0.001; CHIP-CE all domains: 
P < 0.001), but only with low-to-moderate strength. Corre-
lation between ADHD severity and HRQoL was significant 
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the effectiveness of therapeutic interventions [8, 9]. For 
example, HRQoL measures can play a role in identifying 
whether a particular treatment improves not only symptoms 
but also broader functioning, or whether treatments impact 
differentially on specific HRQoL domains. This informa-
tion can lead to opportunities for the tailoring of treatments 
to address particular functional domains at either the indi-
vidual or group level. Furthermore, regulatory authorities 
and reimbursement agencies believe indices of HRQoL can 
play an important role in their decision-making processes 
[9]. However, it is still the case that varying interpretations 
of the general construct and specific HRQoL domains, lim-
ited information concerning the agreement between self 
and proxy raters, lack of consensus with respect to the best 
HRQoL instruments to use, and lack of head-to-head com-
parative studies using psychometrically validated HRQoL 
instruments limit the usefulness of current measures [10]. 
Further validation of HRQoL measures to determine appro-
priate indices of reliable and clinically significant changes 
following therapy is required [11].
Attention-deficit/hyperactivity disorder is the most com-
mon behavioural childhood disorder and has a global prev-
alence in children of approximately 3.4–7.1 % [12–15]. It 
is characterized by developmentally inappropriate levels of 
hyperactivity/impulsivity and/or inattention, which impact 
many aspects of daily life and have a substantial burden 
on family functioning [16–18]. QoL in individuals with 
ADHD is impaired compared to that in individuals with-
out the disorder [2, 3, 19, 20]. While the overall impact 
of ADHD on HRQoL has been reported to be comparable 
with other mental health conditions and physical disorders, 
including diabetes [3, 21–23], disparity still exists regard-
ing the perceived impact of psychiatric and physical disor-
ders, which can adversely affect aspects of mental health 
care provision such as funding allocation within health ser-
vices [24]. ADHD also impacts negatively on the HRQoL 
of the parents/carers of those with the condition [25]. 
Unfortunately, most studies to date have only used parent/
carer ratings [3], and our understanding of the child/adoles-
cent’s views of their own HRQoL is limited. There are also 
only limited data on the association between clinical status 
and HRQoL.
To help address these issues, we conducted a cross-
sectional investigation into the HRQoL of children with 
ADHD, a symptomatic (psychiatric) disorder, compared 
with that of children with type 1 diabetes mellitus (T1DM) 
and healthy controls. The ADHD and diabetic clinics from 
which patients were recruited for this study were responsi-
ble for all cases of these disorders within the local popula-
tion and, therefore, had a broad range of presentations and 
clinical status, representative of local clinical practice. Both 
ADHD and T1DM are chronic disorders for which daily 
treatment is often required. Daily requirements for T1DM, 
such as the regular monitoring of blood sugar, balancing of 
insulin doses and managing of injections, are often difficult 
for parents/carers and children alike.
Findings on HRQoL in T1DM vary. While several stud-
ies have reported reduced HRQoL and particular disease-
specific HRQoL issues, others have not [26–28]. Since 
starting our study, another research group has evaluated 
HRQoL in children aged 5–18 years with ADHD and 
comorbid psychiatric disorders compared with children 
with T1DM using patient- and parent-rated versions of the 
PedsQL [22]. In contrast to the current study, Limbers et al. 
focussed on the use of the PedsQL and did not evaluate 
HRQoL using any other instruments. The authors reported 
significantly poorer HRQoL in children with ADHD and 
comorbid psychiatric disorders compared with children 
with T1DM, supporting our inclusion of children with 
T1DM as a comparator in the current study.
Here, we report responses from children (6–16 years) 
with ADHD, T1DM or healthy controls, and their par-
ents/carers, using two very different but commonly used 
validated generic paediatric HRQoL instruments: the 
PedsQL and the CHIP-CE questionnaires [29–32]. Our pri-
mary question was whether ADHD and T1DM impact on 
HRQoL, as measured by child and parent/carer ratings from 
these two different instruments. We also investigated the 
relationship between HRQoL and disease severity among 
the children with ADHD and T1DM. We hypothesized 
that compared with healthy children, children with ADHD 
and T1DM will both have significantly worse HRQoL, as 
rated by both self and parents/carers on both the PedsQL 
and CHIP-CE, and that better clinical status in ADHD and 
T1DM would be associated with better HRQoL.
Methods
Study design
Boys and girls aged 6–16 years were recruited from three 
outpatient services in Dundee, Scotland (ADHD, diabetic 
and dental). The dental clinics provide general dental ser-
vices to the same local population as the ADHD and dia-
betic clinics; those invited to participate in this study were 
attending for a general check-up rather than specific treat-
ments or emergency care. Postal invitations with an expla-
nation and outline of study purpose were sent to all parents/
carers of children attending the clinics via their respective 
clinical service or dentist (control group) prior to booked 
clinic appointments. If both the parent/carer and child 
could not participate, recruitment of either the parent/carer 
or child was acceptable.
The ADHD group consisted of children diagnosed with 
ADHD by an experienced child and adolescent psychiatrist 
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trained in research methods, following a structured clini-
cal assessment and using Diagnostic and Statistical Man-
ual of Mental Disorders-IV criteria. Children were con-
secutive attendees at an ADHD continuing care clinic 
within the Tayside child and adolescent mental health 
service (CAMHS) at the Centre for Child Health, Dundee 
between September 2008 and January 2011. All children 
were receiving routine clinical care from the CAMHS ser-
vice, which could include psychosocial and/or pharmaco-
logical treatment, or no treatment, for ADHD at the time 
of the study. The T1DM group consisted of children with 
T1DM (diagnosed subsequent to a fasting plasma glucose 
>7.8 mmol/L or random plasma glucose >11.1 mmol/L on 
two occasions; or glucose tolerance test: fasting plasma 
glucose >7.8 mmol/L and plasma glucose >11.1 mmol/L 
2 h post 75 g oral glucose) who were attending a diabetic 
clinic at Ninewells Hospital, Dundee between September 
2010 and July 2011 as part of their routine clinical care. 
The community control group consisted of children/ado-
lescents attending the Lochee Dental Practice, Kings Cross 
Hospital or Dundee Dental Hospital between January 2012 
and January 2013.
In the ADHD group, children were excluded if they 
had a history or current clinical diagnosis of other mental 
health disorders (i.e. bipolar disorder, cyclothymia, psycho-
sis, major depressive disorder, eating disorder, clinically 
significant anxiety disorder or post-traumatic stress disor-
der, pervasive developmental disorder/autistic spectrum 
disorder), or who had moderate or severe intellectual dis-
ability (IQ < 50), or T1DM or any chronic medical con-
dition requiring specialist treatment or requiring hospital 
admission for >24 h within the past year that may impact 
on HRQoL. Children with comorbid psychiatric disorders 
such as oppositional defiant disorder and conduct disorder 
were included in the study to increase the representative-
ness of the sample; however, these conditions must have 
been judged by the clinical team to be secondary to ADHD 
and not currently requiring treatment. In the T1DM group, 
children with a history or current diagnosis of mental 
health disorders (as above) or ADHD were excluded. In the 
control group, exclusion criteria were the same as for the 
ADHD and T1DM groups. Respondents who were consid-
ered unable to understand or complete questionnaires were 
also excluded from all study groups. No compensation was 
received for participating in the study.
Sample size for the primary outcome was calculated 
using data from previous HRQoL studies in ADHD [21, 
33, 34]. At least 20 children per group were required to 
detect an effect size of at least 0.4 between the ADHD 
and control groups with an α error level of 5 % and a 
β error level of 50 % [35]. However, as we were also 
interested in comparisons between parent/carer and 
child outcomes, and between clinical and HRQoL 
outcomes, we elected to recruit a larger convenience 
sample.
Data collection
The assessment procedure was the same for all groups, 
with questionnaire instructions provided in a standardized 
format and according to questionnaire-specific recommen-
dations. The parent/carer and child completed question-
naires independently. A research assistant was available to 
ensure that the content and study procedures were under-
stood and to check for completeness/missing data.
Two generic measures of HRQoL were used: 1) the 
child-self report and parent-proxy report versions of the 
PedsQL, which comprises four domains (physical, emo-
tional, social functioning and school functioning) and 
a total score; and 2) the longer child-report and parent-
report versions of the CHIP-CE, which comprises five 
domains (satisfaction, comfort, resilience, risk avoidance 
and achievement) but no total score. Both scales have been 
shown to be reliable and valid [29–32]. For both instru-
ments, higher scores indicate better HRQoL.
Demographic data and medication status, as appro-
priate, were collected. Data on disease severity were col-
lected for the ADHD group using the ADHD Rating Scale-
IV (ADHD-RS-IV), completed by the clinician following 
interview with the parent/carer, and for the T1DM group 
using percentage glycated haemoglobin (HbA1C) [36, 
37]. Socioeconomic status (SES) was measured using the 
Scottish Index of Multiple Deprivation (SIMD) [38] rank 
score. The SIMD ranks the 6505 geographical data zones 
that cover Scotland from most deprived (ranked 1) to least 
deprived (ranked 6505).
Statistical analysis
All analyses were conducted using SPSS for Windows 
(v.21, SPSS Inc., Chicago, USA). Missing data were han-
dled as per the scoring instructions for each instrument. 
Descriptive analyses [mean and standard deviation (SD)] 
were conducted for demographics and clinical variables. 
The scores for each HRQoL measurement completed by 
parents/carers and children with ADHD were compared 
with the responses from those with T1DM and healthy 
controls. All HRQoL and age data met assumptions of nor-
mality and homogeneity of variance group differences, and 
were analysed using multivariate analysis of covariance 
and thereafter by determination of simple effects through 
planned contrasts [39]. Correlations between child- and 
parent/carer-rated HRQoL, and between disorder severity 
and HRQoL, were tested using two-tailed bivariate correla-
tions and reported using Pearson’s correlation coefficient. 
Statistical significance was set at P < 0.05.
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Results
Overall, 484 invitations were distributed (263 in the 
ADHD group, 74 in the T1DM group and 147 in the 
control group). In total, 388 children and parents/carers 
agreed to participate (80 %). All children and/or their 
parents/carers completed HRQoL measurements: 213 
in the ADHD group, 58 in the T1DM group and 117 in 
the control group. There were significant differences 
between the groups with respect to age, sex and SES 
(Table 1). Children in the control group were younger 
than those in the ADHD and T1DM groups (mean age 
10.1 vs 12.2 and 12.1 years, respectively) and there 
were more males in the ADHD group than in the T1DM 
and control groups (89.2 vs 43.1 % and 41.0 %, respec-
tively). The T1DM group had a higher mean [SD] SIMD 
rank score (higher SES) than the ADHD and control 
groups (3239 [1954] vs 2449 [1796] and 2207 [1987], 
respectively); SES was similar in the ADHD and control 
groups.
As would be expected for a group of children in rou-
tine clinical care, there was a broad spectrum of symptom 
severity in the ADHD group. ADHD rating scale scores 
were normally distributed (Table 1). Age was included as 
a covariate in the analyses as it was significantly corre-
lated with HRQoL domains on the PedsQL parent (school 
functioning, total score) and child (school functioning) 
scales, and the CHIP-CE parent (satisfaction, resilience, 
risk avoidance, achievement) and child (all five domains) 
scales. In all cases, increasing age was associated with 
lower HRQoL, except for the comfort domain on the child-
rated CHIP-CE scale, for which increasing age was associ-
ated with improved HRQoL. SIMD rank was also included 
as a covariate owing to correlations between SIMD rank 
scores and PedsQL parent (social and school functioning, 
total score) and child (school functioning) scales, and the 
CHIP-CE parent (risk avoidance) and child (comfort) rat-
ings. Lower SES was associated with a lower HRQoL. 
There were no significant differences in any domain of any 
scale for any of the groups with respect to sex; therefore, 
sex was not included as a covariate in the analyses. The 
HRQoL scores for the control group were consistent with 
population norms [30, 31, 40].
Between‑group comparisons
Compared with the T1DM and control groups, children 
with ADHD had significantly lower PedsQL ratings (indi-
cating poorer HRQoL) across all domains for both self 
and parent/carer ratings (P < 0.001; Tables 2, 3). For the 
CHIP-CE, there were again significantly lower ratings 
(P < 0.05 to <0.001) for the ADHD group compared with 
both control and T1DM groups for all parent/carer-rated 
domains and for child ratings on the comfort, risk avoid-
ance and achievement domains (Tables 4, 5). Mean scores 
were similar for the T1DM and control groups for both the 
parent/carer-rated and the child-rated HRQoL domains of 
both instruments.
Association between parent/carer and child ratings
Parent/carer and child ratings were significantly correlated 
across the different domains for both measures of HRQoL, 
apart from the social functioning and school functioning 
domains of the PedsQL (Table 6). However, these cor-
relations were only low to moderate in strength (PedsQL 
total score: r = 0.546, P < 0.001; CHIP-CE all domains: 
r > 0.274, P < 0.001). Domains demonstrating significant 
correlations largely remained significant when data were 
analysed separately by study group and by age for chil-
dren aged 6 to <11 years and adolescents aged ≥11 years 
(Table 6).
Table 1  Child/adolescent demographics by study group
ADHD attention-deficit/hyperactivity disorder, NA not available, SD standard deviation, SIMD Scottish Index of Multiple Deprivation, 
T1DM  type 1 diabetes mellitus
* One-way analysis of variance F test (degrees of freedom: 2, 385) = 25.5
** Pearson χ2 (2) = 98.2, n = 387
*** One-way analysis of variance F test (degrees of freedom: 2, 385) = 4.1
a Measure of socioeconomic status
ADHD group (n = 213) T1DM group (n = 58) Control group (n = 117) P value
Mean (SD) age, years 12.2 (2.7) 12.1 (2.5) 10.1 (2.8) <0.001*
Males, n (%) 190 (89.2) 25 (43.1) 48 (41.0) <0.001**
Mean (SD) SIMD ranka 2449 (1796) 3239 (1954) 2207 (1987) 0.018***
Disease severity
 Mean ADHD rating scale total score (range; SD) 23.5 (1–50; 10.0) NA NA –
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Association between HRQoL and disease severity
For the ADHD group, disease severity (ADHD-RS-IV) and 
HRQoL were significantly correlated for all parent/carer 
ratings and for most child ratings (except PedsQL physi-
cal functioning and CHIP-CE satisfaction and resilience) 
on both HRQoL scales (Table 7). In all cases, more ADHD 
symptoms were associated with poorer HRQoL. Correla-
tions were again in the low-to-moderate range and were 
higher for parent/carer ratings than for child ratings. For 
the T1DM group, the only significant correlations between 
disease severity (HbA1C) and HRQoL were for child-rated 
school functioning on the PedsQL scale (r = −0.343, 
P = 0.02), and child-rated satisfaction (r = −0.292, 
P = 0.03), resilience (r = −0.304, P = 0.02) and risk 
avoidance (r = −0.303, P = 0.03) on the CHIP-CE scale 
(Table 7). Where there were significant correlations, worse 
diabetic control was associated with poorer HRQoL.
Discussion
This study provides child- and parent/carer-rated HRQoL 
data from two validated instruments for children with ADHD 
receiving routine clinical care, children with T1DM and 
healthy controls. Despite being on treatment, the reported 
HRQoL of children with ADHD was lower than those of 
the T1DM or control groups for all parent/carer ratings with 
both instruments, all child ratings with PedsQL and most 
child ratings with CHIP-CE. Results for PedsQL-measured 
HRQoL are consistent with previous findings from Limbers 
et al. in children with ADHD and comorbid psychiatric dis-
orders compared with children with T1DM [22]. Limbers 
et al. specifically selected children with ADHD and comor-
bid psychiatric disorders, including mood, anxiety, psychotic 
and substance use disorders, learning disabilities/mental 
retardation and other psychiatric disorders, to reflect the high 
prevalence of comorbidities in patients attending a Pediatric 
Psychiatric Clinic. Children with mental health disorders that 
were not secondary to ADHD or which required treatment 
were excluded from the current study, suggesting that the 
negative impact of ADHD on HRQoL is measureable in the 
absence of cormorbid psychiatric disorders, such as mood, 
anxiety, psychotic and substance use disorders, which may 
themselves reduce HRQoL. It should be noted that children 
with ADHD and chronic medical conditions requiring spe-
cialist medical attention were also excluded from the cur-
rent study. Evidence is emerging to suggest that children 
with ADHD may have an increased risk for certain medical 
conditions compared with children without the disorder, for 
Table 2  PedsQL parent/carer scores by study group
ADHD attention-deficit/hyperactivity disorder, df degrees of freedom, MANCOVA multivariate analysis of covariance, PedsQL Paediatric Quality 
of Life Inventory, SD standard deviation, SE standard error, T1DM type 1 diabetes mellitus
a n = 206 in ADHD group, n = 54 in T1DM group and n = 110 in control group
b Adjusted for age and socioeconomic status
c For adjusted mean score
d Effect size (δ): T1DM vs control (School functioning) = 0.55
Domain Study 
groupa
Unadjusted 
mean score 
(SD)
Adjusted 
mean  
scoreb (SE)
95 % 
confidence 
intervalc
MANCOVA Effect size (δ)
F test df P value ADHD vs 
Control
ADHD vs 
T1DM
Physical  
functioning
ADHD 73.7 (18.6) 73.4 (1.4) 70.7, 76.2 24.2 2, 327 <0.001 ADHD < Control, 
T1DM
0.96 0.90
T1DM 87.8 (12.9) 87.0 (3.0) 81.1, 92.9
Control 89.3 (14.1) 90.1 (2.1) 86.0, 94.1
Emotional 
functioning
ADHD 53.4 (22.2) 53.0 (1.7) 49.7, 56.3 53.6 2, 327 <0.001 ADHD < Control, 
T1DM
1.46 1.27
T1DM 77.3 (16.0) 76.3 (3.6) 69.3, 83.4
Control 81.6 (17.1) 82.9 (2.5) 78.0, 87.8
Social  
functioning
ADHD 62.9 (25.5) 62.5 (1.8) 58.9, 66.1 45.0 2, 327 <0.001 ADHD < Control, 
T1DM
1.38 1.18
T1DM 87.5 (16.6) 85.8 (3.9) 78.2, 93.4
Control 90.2 (14.5) 91.8 (2.7) 86.5, 97.0
School  
functioning
ADHD 52.2 (21.2) 52.0 (1.5) 49.0, 55.1 92.9 2, 327 <0.001 ADHD < T1DM  
< Controld
2.08 1.50
T1DM 79.5 (16.0) 78.0 (3.2) 71.5, 84.4
Control 87.7 (14.1) 88.6 (2.3) 84.2, 93.1
Total score ADHD 62.1 (16.5) 61.8 (1.2) 59.4, 64.2 78.8 2, 327 <0.001 ADHD < Control, 
T1DM
1.61 1.51
T1DM 83.8 (12.5) 82.6 (2.6) 77.5, 87.8
Control 87.2 (11.8) 88.2 (1.8) 84.6, 91.8
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Table 3  PedsQL child scores by study group
ADHD attention-deficit/hyperactivity disorder, df degrees of freedom, MANCOVA multivariate analysis of covariance, PedsQL Paediatric Quality 
of Life Inventory, SD standard deviation, SE standard error, T1DM type 1 diabetes mellitus
a n = 174 in ADHD group, n = 45 in T1DM group and n = 106 in control group
b Adjusted for age and socioeconomic status
c For adjusted mean score
d Effect size (δ): T1DM vs control (School functioning) = 0.69, T1DM vs control (total score) = 0.36
Domain Study 
groupa
Unadjusted 
mean score 
(SD)
Adjusted  
mean scoreb 
(SE)
95 % 
confidence 
intervalc
MANCOVA Effect size (δ)
F test df P value ADHD vs 
Control
ADHD vs 
T1DM
Physical  
functioning
ADHD 79.0 (15.7) 78.3 (1.2) 76.0, 80.7 14.2 2, 321 <0.001 ADHD < Control, 
T1DM
0.57 0.60
T1DM 87.4 (12.2) 86.8 (2.5) 81.8, 91.7
Control 87.7 (14.9) 89.3 (1.8) 85.8, 92.7
Emotional 
functioning
ADHD 69.5 (21.7) 68.9 (1.7) 65.6, 72.2 14.9 2, 321 <0.001 ADHD < Control, 
T1DM
0.75 0.45
T1DM 78.7 (19.2) 77.4 (3.4) 70.7, 84.2
Control 83.5 (15.6) 85.2 (2.4) 80.5, 90.0
Social  
functioning
ADHD 76.0 (22.5) 75.0 (1.7) 71.6, 78.3 14.8 2, 321 <0.001 ADHD < Control, 
T1DM
0.62 0.59
T1DM 86.9 (14.3) 85.3 (3.5) 78.4, 92.2
Control 88.5 (18.0) 91.2 (2.5) 86.3, 96.0
School  
functioning
ADHD 60.8 (21.8) 61.0 (1.7) 57.7, 64.4 32.8 2, 321 <0.001 ADHD < T1DM  
< Controld
1.37 0.61
T1DM 73.7 (20.8) 73.5 (3.5) 66.6, 80.4
Control 86.3 (16.0) 86.0 (2.5) 81.1, 90.9
Total score ADHD 72.1 (15.5) 71.5 (1.2) 69.2, 73.9 30.7 2, 321 <0.001 ADHD < T1DM  
< Controld
1.07 0.72
T1DM 82.2 (12.4) 81.3 (2.4) 76.5, 86.1
Control 86.6 (11.8) 88.0 (1.7) 84.6, 91.4
Table 4  CHIP-CE parent/carer scores by study group
ADHD attention-deficit/hyperactivity disorder, CHIP-CE Child Health and Illness Profile–child edition, df degrees of freedom, 
MANCOVA multivariate analysis of covariance, SD standard deviation, SE standard error, T1DM type 1 diabetes mellitus
a n = 173 in ADHD group, n = 42 in T1DM group and n = 100 in control group
b Adjusted for age and socioeconomic status
c For adjusted mean score
Domain Study 
groupa
Unadjusted 
mean score 
(SD)
Adjusted  
mean scoreb 
(SE)
95 % 
confidence 
intervalc
MANCOVA Effect size (δ)
F test df P value ADHD vs 
Control
ADHD vs 
T1DM
Satisfaction ADHD 32.9 (16.3) 34.2 (1.3) 31.6, 36.8 8.7 2, 311 <0.001 ADHD < Control, 
T1DM
0.68 0.81
T1DM 44.1 (11.5) 45.5 (2.9) 39.8, 51.2
Control 44.1 (16.7) 41.1 (1.9) 37.3, 44.8
Comfort ADHD 42.5 (13.5) 42.4 (1.0) 40.4, 44.4 19.9 2, 311 <0.001 ADHD < Control, 
T1DM
0.93 0.76
T1DM 51.3 (9.7) 51.0 (2.3) 46.4, 55.5
Control 53.5 (10.3) 53.7 (1.5) 50.7, 56.7
Resilience ADHD 37.7 (14.7) 38.9 (1.1) 36.7, 41.0 3.8 2, 311 0.022 ADHD < Control, 
T1DM
0.62 0.46
T1DM 43.6 (11.2) 44.7 (2.4) 40.0, 49.4
Control 45.7 (11.0) 43.0 (1.6) 39.9, 46.1
Risk  
avoidance
ADHD 28.7 (15.5) 28.5 (1.1) 26.3, 30.6 79.0 2, 311 <0.001 ADHD < Control, 
T1DM
1.88 1.84
T1DM 49.7 (8.2) 48.8 (2.4) 44.0, 53.6
Control 50.7 (8.9) 51.5 (1.6) 48.3, 54.7
Achievement ADHD 31.8 (12.0) 32.2 (0.9) 30.5, 34.0 73.5 2, 311 <0.001 ADHD < Control, 
T1DM
1.96 1.57
T1DM 48.7 (9.9) 48.7 (2.0) 44.8, 52.5
Control 50.7 (7.8) 50.0 (1.3) 47.3, 52.5
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example, obesity and asthma [41, 42]. It is likely that the 
burden of illness for children with ADHD may be greater 
than reported here.
The PedsQL and CHIP-CE are both modular, multi-
domain, validated, generic HRQoL measures with child 
and proxy ratings. The findings were generally consistent 
Table 5  CHIP-CE child scores by study group
ADHD attention-deficit/hyperactivity disorder, CHIP-CE Child Health and Illness Profile–child edition, df degrees of freedom, 
MANCOVA multivariate analysis of covariance, NS not significant, SD standard deviation, SE standard error, T1DM type 1 diabetes mellitus
a n = 180 in ADHD group, n = 46 in T1DM group and n = 106 in control group
b Adjusted for age and socioeconomic status
c For adjusted mean score
Domain Study 
groupa
Unadjusted 
mean score 
(SD)
Adjusted  
mean scoreb 
(SE)
95 % 
confidence 
intervalc
MANCOVA Effect size (δ)
F test df P value ADHD vs 
Control
ADHD vs 
T1DM
Satisfaction ADHD 44.5 (11.1) 45.1 (0.9) 43.3, 47.0 0.5 2, 328 NS ADHD = Con-
trol = T1DM
NS NS
T1DM 43.7 (10.3) 44.8 (1.9) 41.0, 48.5
Control 45.2 (12.0) 43.4 (1.4) 40.8, 46.1
Comfort ADHD 53.5 (8.6) 53.0 (0.7) 51.7, 54.3 5.0 2, 328 0.008 ADHD < Control, 
T1DM
0.17 0.51
T1DM 57.1 (5.1) 56.2 (1.4) 53.5, 58.9
Control 54.9 (7.8) 56.3 (1.0) 54.4, 58.1
Resilience ADHD 43.9 (10.8) 44.3 (0.8) 42.6, 45.9 2.3 2, 328 NS ADHD = Con-
trol = T1DM
NS NS
T1DM 47.2 (9.7) 47.8 (1.7) 44.3, 51.1
Control 47.4 (7.9) 46.5 (1.2) 44.1, 48.9
Risk avoidance ADHD 39.8 (10.7) 40.4 (0.8) 38.9, 41.9 30.1 2, 328 <0.001 ADHD < Control, 
T1DM
1.47 0.76
T1DM 47.4 (9.3) 47.9 (1.6) 44.8, 51.0
Control 51.9 (5.7) 50.4 (1.1) 48.2, 52.6
Achievement ADHD 39.4 (11.3) 39.7 (0.9) 38.0, 41.5 10.0 2, 328 <0.001 ADHD < Control, 
T1DM
0.25 0.72
T1DM 46.7 (9.0) 47.0 (1.8) 43.5, 50.6
Control 42.2 (10.9) 45.0 (1.3) 42.5, 47.5
Table 6  Correlations between parent/carer and child ratings of HRQoL measurements
ADHD attention-deficit/hyperactivity disorder, CHIP-CE Child Health and Illness Profile–child edition, HRQoL health-related quality of life, 
PedsQL Paediatric Quality of Life Inventory, T1DM type 1 diabetes mellitus
Pearson’s correlation: * P < 0.05, ** P < 0.01, *** P < 0.001
PedsQL Physical functioning Emotional functioning Social functioning School functioning Total score
All children (n = 335) 0.357*** 0.439*** 0.080 0.097 0.546***
ADHD (n = 199) 0.289*** 0.365*** 0.081 0.107 0.440***
T1DM (n = 51) 0.518*** 0.395*** 0.313* 0.500*** 0.616***
Control (n = 117) 0.231* 0.280** 0.162 0.322** 0.290**
Age group
 6 to <11 years (n = 138) 0.279*** 0.390*** 0.385*** 0.497*** 0.453***
 ≥11 years (n = 222) 0.405*** 0.475*** 0.102 0.113 0.593***
CHIP-CE Satisfaction Comfort Resilience Risk avoidance Achievement
All children (n = 339) 0.274*** 0.302*** 0.310*** 0.647*** 0.517***
ADHD (n = 205) 0.380*** 0.325*** 0.283*** 0.534*** 0.442***
T1DM (n = 54) 0.466** 0.491** 0.320* 0.648*** 0.540***
Control (n = 116) 0.146 0.188* 0.205* 0.333*** 0.417***
Age group
 6 to < 11 years (n = 142) 0.122 0.220* 0.188* 0.483*** 0.413***
 ≥11 years (n = 231) 0.348*** 0.394*** 0.356*** 0.719*** 0.558***
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for the two different instruments; further analyses are 
required to identify whether both instruments are measur-
ing similar aspects of HRQoL or whether they are indexing 
similar levels of disruption across different aspects.
The effect sizes for parent/carer and child ratings were 
similar for both instruments, although the strength of effect 
was somewhat less for several of the child-completed 
CHIP-CE domains than was seen for the other measures. 
Parent and child ratings were significantly correlated with 
each other on both scales. However, the strength of both 
effect and correlation varied by domain, and child–parent/
carer correlations did not reach significance for the social 
functioning and school functioning domains of the PedsQL. 
Our findings of a strong child-rated effect on the PedsQL 
and several of the CHIP-CE domains contrast with previ-
ous studies that reported reductions in parent but not child-
rated HRQoL in ADHD [3, 22, 43–45]. This has often been 
interpreted as a tendency for children with ADHD to mini-
mize their difficulties [3]. The finding that the child-rated 
PedsQL scores were more consistently reduced than those 
for the CHIP-CE may indicate that some of the previous 
findings may be instrument dependent. However, the lower 
child–parent/carer correlations on some PedsQL domains 
suggest a more complex relationship between the two ver-
sions of the two instruments. Interestingly, when these 
correlations were looked at by age group, the adolescent–
parent/carer correlations tended to be stronger than those 
for child–parent/carer in this study, apart from the social 
functioning and school functioning PedsQL domains. One 
might have expected parents/carers to have been more in 
tune with the younger children than the adolescents who 
spend more time outside the home/with peers. However, 
the positive correlations between scores in parents/carers 
and children of all ages suggest that parents/carers are rea-
sonably good at assessing the QoL of their children. While 
adolescents are also good at evaluating their own QoL, 
younger children may not grasp the concepts and con-
structs presented by the instruments and are thus less able 
to give an accurate account.
In contrast to the limited correlations between disease 
severity and HRQoL for T1DM, the correlations between 
disease severity and ADHD were significant on both 
scales for all parent/carer and most child ratings (although 
PedsQL seemed more sensitive for the child ratings than 
CHIP-CE). However, these correlations were only low 
to moderate in strength, suggesting that, although there 
is overlap between the two, they are assessing different 
aspects of functioning. Both disease severity and quality of 
care impact HRQoL and, in the present study, fewer symp-
toms were associated with better HRQoL. These findings 
clearly carry a significant message to those delivering clini-
cal care to patients with ADHD: that optimizing sympto-
matic control will have a positive impact on HRQoL. This 
is important as most studies investigating quality of routine 
Table 7  Correlations between parent/carer and child ratings of HRQoL and disease severity data
ADHD attention-deficit/hyperactivity disorder, ADHD-RS-IV ADHD Rating Scale-IV, CHIP-CE Child Health and Illness Profile–child edition, 
HbA1C glycated haemoglobin, HRQoL health-related quality of life, PedsQL Paediatric Quality of Life Inventory, T1DM type 1 diabetes mellitus
Pearson’s correlation: * P < 0.05, ** P < 0.01, *** P < 0.001
ADHD group (ADHD-RS-IV)
PedsQL Physical functioning Emotional functioning Social functioning School functioning Total score
Parent/carer ratings −0.296** −0.451*** −0.387*** −0.542*** −0.545***
Child ratings −0.119 −0.302** −0.244* −0.292** −0.277**
ADHD group (ADHD-RS-IV)
CHIP-CE Satisfaction Comfort Resilience Risk avoidance Achievement
Parent/carer ratings −0.302*** −0.351** −0.290** −0.433*** −0.453***
Child ratings −0.092 −0.306** 0.074 −0.354** −0.236*
T1DM group (HbA1C)
PedsQL Physical functioning Emotional functioning Social functioning School functioning Total score
Parent/carer ratings −0.256 −0.174 −0.166 −0.001 −0.144
Child ratings −0.223 −0.118 0.074 −0.343* −0.176
T1DM group (HbA1C)
CHIP-CE Satisfaction Comfort Resilience Risk avoidance Achievement
Parent/carer ratings 0.022 −0.173 −0.089 −0.051 −0.018
Child ratings −0.292* −0.250 −0.304* −0.303* −0.152
269Eur Child Adolesc Psychiatry (2016) 25:261–271 
1 3
clinical care suggest that treatment outcomes are often not 
optimized [46] and that clinicians tend to be satisfied with 
identifying some improvement rather than striving to maxi-
mize symptom reduction [47]. The Multimodal Treatment 
of ADHD (MTA) study clearly demonstrated that closely 
managed treatment was superior to treatment in the com-
munity [48]. Even though these findings are mentioned in 
many clinical guidelines, there is currently little evidence 
that they have been implemented in routine clinical practice 
(although evidence-based clinical protocols are beginning 
to emerge) (Coghill D, Personal communication, 25 Janu-
ary 2014). Although ADHD symptoms and HRQoL were 
correlated in this study, it is still possible that the PedsQL 
and CHIP-CE scales are measuring different aspects of the 
problems faced by those with ADHD. Correlations between 
symptoms and HRQoL are far from perfect, suggesting 
that, even if symptoms are optimally treated, there are still 
likely to be other factors that need to be addressed to opti-
mize HRQoL and clinical functioning.
The HRQoL of participants with T1DM in this study 
was not impaired compared with the control group. 
Although these findings were not expected at the outset 
of the study, they are in keeping with the results of a more 
recent systematic review [49]. Although the authors of this 
review concluded that T1DM does not impact negatively on 
HRQoL as measured by generic instruments (such as those 
used in the current study), they noted that disease-specific 
impairments in HRQoL are present in children with T1DM. 
This finding may reflect greater attention being paid to 
optimizing care in this patient group and/or a lower impact 
of T1DM on day-to-day functioning than ADHD. At the 
very least, these data support current attempts seeking par-
ity in mental and physical health services [50].
The limitations of this cross-sectional HRQoL study 
include non-response to study invitations, which can result in 
bias, and as data on non-responders were unavailable, differ-
ences in the demographic and disease characteristics between 
responders and non-responders could not be evaluated. In 
addition, group sizes were not equally matched and there 
were age, sex and SES differences between groups. The bias 
towards males observed in the ADHD group is typical of clin-
ical samples; however, sex did not appear to affect HRQoL, 
and age and SES were adjusted for in the analyses. While 
patients attending the ADHD and T1DM clinics were initially 
referred for treatment and, therefore, not an epidemiological 
sample, attendees were recruited sequentially from the whole 
clinic populations. Although patients in the ADHD group 
were receiving clinical care for ADHD, medication status was 
not collected and could not be included in the analyses. As 
parents/carers and children both contributed information to 
the clinician-scored ratings of ADHD symptoms (ADHD-RS-
IV) and HRQoL, these ratings were not entirely independent 
of each other. This may have inflated the correlations between 
the two. However, while correlations between these measures 
were significant, they were not highly correlated, supporting 
the value of measuring HRQoL in addition to symptoms.
These data demonstrate that ADHD has a significant 
impact on generic HRQoL, and that this appears to be greater 
than seen for T1DM. This impact also appears to be related to 
ADHD severity and, importantly, is observed in both parent/
carer and child ratings. We consider that these findings should 
be generalizable, at least for a referred population of patients. 
Furthermore, the degree of impairment of HRQoL reported 
here is similar to that seen in other studies, and agreement 
was observed between the parents/carers and children, and 
between the two measures. However, the findings are pre-
liminary and it may be prudent to obtain ratings from both 
instruments for an accurate scientific perspective of HRQoL. 
We believe that further studies are necessary to obtain a con-
sensus opinion of the validity and value of HRQoL measures.
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